Wells Fargo
OBIO icon

Wells Fargo’s Orchestra BioMed OBIO Stock Holding History

Wells Fargo’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,474
Closed -$12K – 7297
2025
Q2 		$12K Sell
4,474
-8,979
-67% -$26.2K ﹤0.01% 5906
2025
Q1 		$57.6K Buy
13,453
+297
+2% +$1.48K ﹤0.01% 5353
2024
Q4 		$52.6K Buy
13,156
+3,992
+44% +$21.4K ﹤0.01% 5466
2024
Q3 		$47.1K Buy
9,164
+140
+2% +$915 ﹤0.01% 5364
2024
Q2 		$73.5K Buy
9,024
+4,576
+103% +$26.5K ﹤0.01% 5116
2024
Q1 		$23.4K Buy
4,448
+585
+15% +$3.96K ﹤0.01% 5537
2023
Q4 		$35.3K Buy
3,863
+863
+29% +$5.89K ﹤0.01% 5401
2023
Q3 		$26.2K Buy
3,000
+1,177
+65% +$7.91K ﹤0.01% 5489
2023
Q2 		$12.8K Buy
1,823
+1,733
+1,926% +$26.3K ﹤0.01% 5846
2023
Q1 		$1.76K Buy
+90
New +$1.04K ﹤0.01% 6252

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's OBIO Position: Q3 2025 in Review

Wells Fargo sold out of Orchestra BioMed (OBIO) in Q3 2025, closing a stake of 4,474 shares — an estimated $12K sold.

Wells Fargo first reported a position in OBIO in Q1 2023 and held it in 10 quarters. The position peaked at $73.5K in Q2 2024. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • Wells Fargo reported no remaining Orchestra BioMed position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 4,474 Orchestra BioMed shares in Q3 2025, an estimated $12K.
  • Wells Fargo first reported a position in Orchestra BioMed in Q1 2023 and held it in 10 quarters.
  • Wells Fargo's Orchestra BioMed position peaked at $73.5K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.